A joint EU–US trade arrangement establishes a single, all-inclusive 15% maximum tariff on specified EU goods, including generic pharmaceuticals, their ingredients, and chemical precursors, effective September 1. The arrangement includes zero-for-zero tariff carve-outs for aircraft and aircraft parts, with additional carve-outs to be determined for certain pharmaceutical and chemical products. Irish officials emphasize that the 15% cap shields exporters, particularly in pharmaceuticals and semiconductors, from potentially larger tariffs tied to ongoing US Section 232 investigations. Negotiations aim to identify further carve-outs and to progress toward a more comprehensive formal agreement with the US.
We welcome clarity that the deal includes a single, all-inclusive 15pc tariff on EU goods," Mr Harris said.
We also now have assurance that this rate will extend to pharmaceuticals and semiconductors. "This provides an important shield to Irish exporters that could have been subject to much larger tariffs pending the outcomes of Section 232 US investigations into these sectors.
Given the scale of the pharmaceutical and semiconductor sectors in Ireland, it is important that the Joint Statement confirms that 15pc is a ceiling that will apply to EU exports in these areas in all circumstances, including when the current US Section 232 investigations are concluded.
Collection
[
|
...
]